Newswise — Several tests have been developed for detecting the genetic material of the SARS-CoV-2 coronavirus that causes COVID-19, but these generally only allow detection of the virus during acute infection. Antibody, or serological, tests are urgently needed to determine the real rate of infection, to understand individuals' antibody responses to the virus, and to identify people who are potentially immune to re-infection. As described in a paper published in Current Protocols in Microbiology, investigators have now developed such a test.
The published article provides a step-by-step protocol with enough detail for other researchers to replicate in their laboratories. The protocol involves expressing and purifying segments of a key SARS-CoV-2 protein that are then used in blood tests for the presence of antiviral antibodies.
"Serological assays can be used to identify individuals who were infected (including severe, mild, and asymptomatic cases) and who are now potentially immune, which means that they are unlikely to transmit the virus to others," the authors wrote. "As an example, healthcare workers who are immune could potentially care for COVID19 patients with minimal risk to themselves, their colleagues, and other patients."
Current Protocols in Microbiology presents clear methodologies for research in priority areas such as emerging and neglected infectious diseases, biodefense, microbe-host interactions, and host defense. As with all of the Current Protocols titles, experts from around the globe, many of whom have invented the methods described, are invited by our editorial board members to contribute their step-by-step protocols and expert advice to ensure that even novice biologist can confidently apply these methods to their own research.
Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company's website can be accessed at http://www.